"Overall, this study demonstrates the feasibility of applying QPOP as a functional combinatorial precision medicine platform to predict therapeutic sensitivities in AML and provides the basis for ...

Data elements obtained from the clinical databases for the three recent multinational openlabel clinical trials included patient age, sex, race, AML classification, the duration of first remission ...

The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell ...

The myeloMATCH precision medicine trials (NCT05564390), funded ... drug combination treatments for patients with newly diagnosed AML and MDS and to treat patients with these aggressive cancers ...